Pharmaceutical Business review

Skinvisible gets European patent notice for Invisicare

The patent protects Invisicare in three main areas: its composition, its method of combining polymers to make the Invisicare complex and the skin / medical conditions Invisicare is used for.

Invisicare drug delivery technology is used in prescription, over-the-counter and cosmeceutical products.

Skinvisible president and CEO Terry Howlett said patent protection provides Skinvisible and its licensees with a marketing advantage over other products using similar active ingredients.

"We expect to reinforce our patent portfolio with new products in high-value disease areas, formulated with the next generation of Invisicare technologies," Howlett said.